Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹8,195 Cr
Revenue (TTM)
₹1,349 Cr
Net Profit (TTM)
₹293 Cr
ROE
44.2 %
ROCE
58 %
P/E Ratio
27.9
P/B Ratio
11.8
Industry P/E
28.7
EV/EBITDA
18.9
Div. Yield
2.5 %
Debt to Equity
0
Book Value
₹420.1
EPS
₹176.8
Face value
10
Shares outstanding
16,599,382
CFO
₹1,398.92 Cr
EBITDA
₹2,190.89 Cr
Net Profit
₹1,583.73 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Procter & Gamble Health
| -13.4 | -3.0 | -13.5 | -4.1 | 0.5 | -5.3 | 22.6 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Procter & Gamble Health
| 9.3 | 5.5 | 25.2 | -26.0 | -23.5 | 54.6 | 38.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Procter & Gamble Health
|
4,939.8 | 8,194.5 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.9 | 11.8 |
| 3,056.6 | 38,176.6 | 5,201.6 | 1,014.6 | 22.9 | 25 | 37.6 | 8.3 | |
| 8,483.5 | 21,239.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 105.7 | 25.5 | |
| 1,648.2 | 12,536.2 | 2,089.5 | 622.0 | 31.3 | 20.4 | 20.4 | 3.8 | |
| 1,308.1 | 18,156.7 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.1 | 5.0 | |
| 2,118.0 | 33,968.6 | 4,193.0 | 753.8 | 22.7 | 20.8 | 45.1 | 8.5 | |
| 4,818.0 | 22,063.4 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.8 | 5.5 | |
| 3,460.8 | 7,974.5 | 1,837.4 | 326.7 | 24.7 | 45.3 | 24.4 | 10.6 | |
| 324.6 | 6,348.6 | 1,432.0 | 149.0 | 19.1 | 7.9 | 42.3 | 2.5 | |
| 907.1 | 8,342.6 | 4,725.6 | 528.7 | 14.9 | 20.7 | 16.3 | 2.8 |
Procter & Gamble Health Limited engages in the manufacture and marketing of pharmaceuticals and chemical products in India and internationally. The company provides over-the-counter products, vitamins, minerals, and supplements. It offers its... products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. The company was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India BV. Read more
Incorporated
1967
Chairman
S Madhavan
Managing Director
Milind Thatte
Group
Merck - MNC
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Procter & Gamble Health Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The share price of Procter & Gamble Health Ltd is ₹4,939.80 (NSE) and ₹4,936.65 (BSE) as of 18-Mar-2026 IST. Procter & Gamble Health Ltd has given a return of 0.5% in the last 3 years.
The P/E ratio of Procter & Gamble Health Ltd is 27.92 times as on 18-Mar-2026, a 3 discount to its peers’ median range of 28.70 times.
The P/B ratio of Procter & Gamble Health Ltd is 11.75 times as on 18-Mar-2026, a 157 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
41.71
|
15.83
|
|
2023
|
37.97
|
11.73
|
|
2022
|
36.10
|
11.41
|
|
2021
|
52.52
|
13.27
|
|
2018
|
50.32
|
3.32
|
The 52-week high and low of Procter & Gamble Health Ltd are Rs 6,739.00 and Rs 4,725.00 as of 19-Mar-2026.
Procter & Gamble Health Ltd has a market capitalisation of ₹ 8,195 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Procter & Gamble Health Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹19.80
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.